A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

Dean Marko Wingerchuk, E. E. Benarroch, P. C. O'Brien, B Mark Keegan, Claudia F Lucchinetti, J. H. Noseworthy, Brian G Weinshenker, M. Rodriguez

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.

Original languageEnglish (US)
Pages (from-to)1267-1269
Number of pages3
JournalNeurology
Volume64
Issue number7
StatePublished - Apr 12 2005

Fingerprint

Cross-Over Studies
Aspirin
Multiple Sclerosis
Fatigue
Randomized Controlled Trials
Double-Blind Method
Placebos
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Wingerchuk, D. M., Benarroch, E. E., O'Brien, P. C., Keegan, B. M., Lucchinetti, C. F., Noseworthy, J. H., ... Rodriguez, M. (2005). A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology, 64(7), 1267-1269.

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. / Wingerchuk, Dean Marko; Benarroch, E. E.; O'Brien, P. C.; Keegan, B Mark; Lucchinetti, Claudia F; Noseworthy, J. H.; Weinshenker, Brian G; Rodriguez, M.

In: Neurology, Vol. 64, No. 7, 12.04.2005, p. 1267-1269.

Research output: Contribution to journalArticle

Wingerchuk, DM, Benarroch, EE, O'Brien, PC, Keegan, BM, Lucchinetti, CF, Noseworthy, JH, Weinshenker, BG & Rodriguez, M 2005, 'A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis', Neurology, vol. 64, no. 7, pp. 1267-1269.
Wingerchuk, Dean Marko ; Benarroch, E. E. ; O'Brien, P. C. ; Keegan, B Mark ; Lucchinetti, Claudia F ; Noseworthy, J. H. ; Weinshenker, Brian G ; Rodriguez, M. / A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. In: Neurology. 2005 ; Vol. 64, No. 7. pp. 1267-1269.
@article{30af85d50b61456187db3926b6b919d5,
title = "A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis",
abstract = "Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.",
author = "Wingerchuk, {Dean Marko} and Benarroch, {E. E.} and O'Brien, {P. C.} and Keegan, {B Mark} and Lucchinetti, {Claudia F} and Noseworthy, {J. H.} and Weinshenker, {Brian G} and M. Rodriguez",
year = "2005",
month = "4",
day = "12",
language = "English (US)",
volume = "64",
pages = "1267--1269",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis

AU - Wingerchuk, Dean Marko

AU - Benarroch, E. E.

AU - O'Brien, P. C.

AU - Keegan, B Mark

AU - Lucchinetti, Claudia F

AU - Noseworthy, J. H.

AU - Weinshenker, Brian G

AU - Rodriguez, M.

PY - 2005/4/12

Y1 - 2005/4/12

N2 - Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.

AB - Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.

UR - http://www.scopus.com/inward/record.url?scp=16844368558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844368558&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1267

EP - 1269

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -